[68Ga]Ga-HER2单域抗体PET/CT在乳腺癌患者中的可重复性与肿瘤摄取II期试验
本II期试验纳入20例局部晚期或转移性乳腺癌患者(5例HER2阳性、15例HER2阴性),评估[68Ga]Ga-NOTA-anti-HER2单域抗体PET/CT的摄取定量可重复性与扩展安全性。结果显示该技术可重复(重复性系数21.8%),PET摄取与病理HER2状态无明确相关性,即使HER2低表达患者也可见中高摄取;与[18F]FDG PET/CT比较,部分患者显示瘤间异质性。16例不良事件均与示踪剂无明确关系,未产生新抗药抗体。结论认为该示踪剂安全,支持进一步临床开发。
要点
- 该技术可重复,重复性系数为21.8%。
- PET/CT摄取值与病理HER2状态无明确相关性,HER2低表达患者也可见中高摄取。
- 16例不良事件均与示踪剂无明确关系,3例预存抗药抗体患者无不良反应,未产生新抗药抗体。
核心结论
- [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT成像的可重复性与[18F]FDG相似,临床使用安全。
- 即使既往判定为HER2低表达或阴性的患者,癌灶仍有示踪剂摄取。
- 该示踪剂在评估HER2表达的瘤间异质性方面有潜力,部分患者中无或低[18F]FDG摄取的病灶可见[68Ga]Ga-NOTA-anti-HER2-sdAb摄取。
- 这些发现支持进一步临床开发[68Ga]Ga-NOTA-anti-HER2-sdAb作为乳腺癌患者的PET/CT示踪剂。
研究设计与样本
- II期试验纳入20例局部晚期或转移性乳腺癌患者,其中5例HER2阳性、15例HER2阴性。
- 注射[68Ga]Ga-NOTA-anti-HER2单域抗体后90分钟行PET/CT扫描,8天内重复该程序。
- 采血进行抗药抗体评估和液体活检,对可用组织行免疫组化、原位杂交和质谱分析以确定HER2状态与PET摄取值的相关性。
- 如存在相关既往[18F]FDG PET/CT图像(按标准诊疗进行),则进行比较。
主要发现
- 该成像技术可重复,重复性系数为21.8%。
- PET/CT摄取值与病理之间未能建立明确相关性,即使HER2低表达患者也显示中高摄取。
- 在16例患者中与[18F]FDG PET/CT比较,7例患者中[68Ga]Ga-NOTA-anti-HER2显示同一患者内的瘤间异质性,而[18F]FDG摄取并非在所有患者中均显示相同的异质性摄取。
- 部分患者中[68Ga]Ga-NOTA-anti-HER2-sdAb显示的病 extent 更清晰。
- 报告16例不良事件,但均与示踪剂无明确关系;3例预存抗药抗体的患者未出现不良反应;未产生新的抗药抗体。
关键数值与推荐
- 重复性系数为21.8%。
- 20例患者中5例HER2阳性、15例HER2阴性。
- 16例患者进行了[18F]FDG PET/CT比较,其中7例显示瘤间异质性。
- 报告16例不良事件,均与示踪剂无明确关系。
- 3例患者预存抗药抗体,未出现不良反应;未产生新抗药抗体。
临床怎么用
- 原文结论认为该示踪剂临床使用安全,并支持进一步临床开发作为乳腺癌PET/CT示踪剂。
- 原文指出该示踪剂在评估HER2表达瘤间异质性方面有潜力。
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human epidermal growth factor receptor 2 (HER2) status is used for decision-making in breast carcinoma treatment. The status is obtained through immunohistochemistry or in situ hybridization. These two methods have the disadvantage of necessitating tissue sampling, which is prone to error due to tumor heterogeneity or interobserver variability. Whole-body imaging might be a solution to map HER2 expression throughout the body. Methods: Twenty patients with locally advanced or metastatic breast carcinoma (5 HER2-positive and 15 HER2-negative patients) were included in this phase II trial to assess the repeatability of uptake quantification and the extended safety of the [68Ga]Ga-NOTA-anti-HER2 single-domain antibody (sdAb). The tracer was injected, followed by a PET/CT scan at 90 min. Within 8 d, the procedure was repeated. Blood samples were taken for antidrug antibody (ADA) assessment and liquid biopsies. On available tissues, immunohistochemistry, in situ hybridization, and mass spectrometry were performed to determine the correlation of HER2 status with uptake values measured on PET. If relevant preexisting [18F]FDG PET/CT images were available (performed as standard of care), a comparison was made. Results: With a repeatability coefficient of 21.8%, this imaging technique was repeatable. No clear correlation between PET/CT uptake values and pathology could be established, as even patients with low levels of HER2 expression showed moderate to high uptake. Comparison with [18F]FDG PET/CT in 16 patients demonstrated that in 7 patients, [68Ga]Ga-NOTA-anti-HER2 shows interlesional heterogeneity within the same patient, and [18F]FDG uptake did not show the same heterogeneous uptake in all patients. In some patients, the extent of disease was clearer with the [68Ga]Ga-NOTA-anti-HER2-sdAb. Sixteen adverse events were reported but all without a clear relationship to the tracer. Three patients with preexisting ADAs did not show adverse reactions. No new ADAs developed. Conclusion: [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT imaging shows similar repeatability to [18F]FDG. It is safe for clinical use. There is tracer uptake in cancer lesions, even in patients previously determined to be HER2-low or -negative. The tracer shows potential in the assessment of interlesional heterogeneity of HER2 expression. In a subset of patients, [68Ga]Ga-NOTA-anti-HER2-sdAb uptake was seen in lesions with no or low [18F]FDG uptake. These findings support further clinical development of [68Ga]Ga-NOTA-anti-HER2-sdAb as a PET/CT tracer in breast cancer patients.
引用
- Gondry O, Caveliers V, Xavier C, et al. Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma. J Nucl Med. 2024. PMID: 38302159. doi:10.2967/jnumed.123.266254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。